The global infertility treatments market size is experiencing significant growth, and is expected to reach USD 3.28 billion by 2033. This expansion is driven by a multitude of factors, including rising infertility, advances in equipment and technology, and the integration of artificial intelligence (AI).
Rising infertility is driving demand
A significant factor behind this staggering market growth is the rise in global infertility rates. The World Health Organization (WHO) estimates that about one in six people worldwide have experienced infertility at some point in their lives. Lifestyle factors, such as delaying parenthood and environmental concerns contribute to this rise.
The study, published by Towards Healthcare, highlights how the growing number of couples facing infertility fueled the expansion of the entire market. The increase in infertility cases creates a greater need for solutions that help people build a family. Clinics are stepping up by offering more services, and new and improved assisted reproductive technologies are emerging in response to this trend. Additionally, increased awareness about infertility and available treatments is empowering more people to actively seek solutions, further propelling market growth.
Advances in technology and the integration of AI
The market continues to benefit from advances in medical technology. The constant development of more effective and accessible ART procedures, like in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), and preimplantation genetic testing (PGT), and higher success rates, encourage more individuals to seek fertility treatment.
The use of AI is also shaping fertility treatment – and the market. The integration of AI into sperm analysis systems is revolutionizing the way specialists select the best sperm for fertilization, further enhancing treatment efficacy. The study highlights how the global AI in medical coding market size was projected at USD 2.06 billion in 2022 to reach around USD 7.15 billion by 2032, staggering a CAGR of 13.3% between 2023 and 2032.
Equipment holds substantive share of the fertility market
Equipment made up the majority of the market in 2023, with a commanding 55% share. This segment encompasses the vital tools employed by fertility clinics to provide fertility care, and perform assisted reproductive technology (ART) procedures and diagnostic tests with precision and accuracy.
MES Global, a world leader in comprehensive lines of CE and FDA approved Sperm Quality Analyzers (SQA) stands at the forefront of this vital equipment sector. Our commitment to innovation ensures clinics have access to the most advanced and cost-effective technology. This translates to improved sperm analysis accuracy, enhanced treatment planning, streamlined workflows, and informed decision-making. Additionally, our laboratory accessories and at-home testing solutions cater to the evolving needs of this growing market, covering both the patient at the clinic and the individual monitoring their fertility in the privacy of their own home.
Key Takeaway
As the market expands to meet the growing demand for effective solutions, advancements in technology and a rising awareness of infertility empower more individuals to seek treatment. Infertility places an emotional toll on those experiencing it and the global outlook points to rising numbers. It’s crucial to acknowledge these rising challenges while remaining hopeful about the growth and innovations that will help so many achieve their dream of parenthood.
